Copyright Reports & Markets. All rights reserved.

Global Pretomanid Tablets Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Pretomanid Tablets Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 26 tablets/box
    • 1.3.3 182 tablets/bottle
  • 1.4 Market Analysis by Packaging
    • 1.4.1 Overview: Global Pretomanid Tablets Consumption Value by Packaging: 2021 Versus 2025 Versus 2032
    • 1.4.2 Bottle
    • 1.4.3 Box
  • 1.5 Market Analysis by Storage
    • 1.5.1 Overview: Global Pretomanid Tablets Consumption Value by Storage: 2021 Versus 2025 Versus 2032
    • 1.5.2 Protect From Light
    • 1.5.3 Protect From Moisture
  • 1.6 Market Analysis by Production Technology
    • 1.6.1 Overview: Global Pretomanid Tablets Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
    • 1.6.2 Innovator
    • 1.6.3 Generic
  • 1.7 Market Analysis by Application
    • 1.7.1 Overview: Global Pretomanid Tablets Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.7.2 Multidrug-Resistant Pulmonary Tuberculosis (MDR-TB)
    • 1.7.3 Extensively Drug-Resistant Pulmonary Tuberculosis (XDR-TB)
    • 1.7.4 Others
  • 1.8 Global Pretomanid Tablets Market Size & Forecast
    • 1.8.1 Global Pretomanid Tablets Consumption Value (2021 & 2025 & 2032)
    • 1.8.2 Global Pretomanid Tablets Sales Quantity (2021-2032)
    • 1.8.3 Global Pretomanid Tablets Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 TB Alliance
    • 2.1.1 TB Alliance Details
    • 2.1.2 TB Alliance Major Business
    • 2.1.3 TB Alliance Pretomanid Tablets Product and Services
    • 2.1.4 TB Alliance Pretomanid Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 TB Alliance Recent Developments/Updates
  • 2.2 Macleods Pharmaceuticals
    • 2.2.1 Macleods Pharmaceuticals Details
    • 2.2.2 Macleods Pharmaceuticals Major Business
    • 2.2.3 Macleods Pharmaceuticals Pretomanid Tablets Product and Services
    • 2.2.4 Macleods Pharmaceuticals Pretomanid Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Macleods Pharmaceuticals Recent Developments/Updates
  • 2.3 Lupin Limited
    • 2.3.1 Lupin Limited Details
    • 2.3.2 Lupin Limited Major Business
    • 2.3.3 Lupin Limited Pretomanid Tablets Product and Services
    • 2.3.4 Lupin Limited Pretomanid Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Lupin Limited Recent Developments/Updates

3 Competitive Environment: Pretomanid Tablets by Manufacturer

  • 3.1 Global Pretomanid Tablets Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Pretomanid Tablets Revenue by Manufacturer (2021-2026)
  • 3.3 Global Pretomanid Tablets Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Pretomanid Tablets by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Pretomanid Tablets Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Pretomanid Tablets Manufacturer Market Share in 2025
  • 3.5 Pretomanid Tablets Market: Overall Company Footprint Analysis
    • 3.5.1 Pretomanid Tablets Market: Region Footprint
    • 3.5.2 Pretomanid Tablets Market: Company Product Type Footprint
    • 3.5.3 Pretomanid Tablets Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Pretomanid Tablets Market Size by Region
    • 4.1.1 Global Pretomanid Tablets Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Pretomanid Tablets Consumption Value by Region (2021-2032)
    • 4.1.3 Global Pretomanid Tablets Average Price by Region (2021-2032)
  • 4.2 North America Pretomanid Tablets Consumption Value (2021-2032)
  • 4.3 Europe Pretomanid Tablets Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Pretomanid Tablets Consumption Value (2021-2032)
  • 4.5 South America Pretomanid Tablets Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Pretomanid Tablets Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Pretomanid Tablets Sales Quantity by Type (2021-2032)
  • 5.2 Global Pretomanid Tablets Consumption Value by Type (2021-2032)
  • 5.3 Global Pretomanid Tablets Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Pretomanid Tablets Sales Quantity by Application (2021-2032)
  • 6.2 Global Pretomanid Tablets Consumption Value by Application (2021-2032)
  • 6.3 Global Pretomanid Tablets Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Pretomanid Tablets Sales Quantity by Type (2021-2032)
  • 7.2 North America Pretomanid Tablets Sales Quantity by Application (2021-2032)
  • 7.3 North America Pretomanid Tablets Market Size by Country
    • 7.3.1 North America Pretomanid Tablets Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Pretomanid Tablets Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Pretomanid Tablets Sales Quantity by Type (2021-2032)
  • 8.2 Europe Pretomanid Tablets Sales Quantity by Application (2021-2032)
  • 8.3 Europe Pretomanid Tablets Market Size by Country
    • 8.3.1 Europe Pretomanid Tablets Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Pretomanid Tablets Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Pretomanid Tablets Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Pretomanid Tablets Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Pretomanid Tablets Market Size by Region
    • 9.3.1 Asia-Pacific Pretomanid Tablets Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Pretomanid Tablets Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Pretomanid Tablets Sales Quantity by Type (2021-2032)
  • 10.2 South America Pretomanid Tablets Sales Quantity by Application (2021-2032)
  • 10.3 South America Pretomanid Tablets Market Size by Country
    • 10.3.1 South America Pretomanid Tablets Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Pretomanid Tablets Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Pretomanid Tablets Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Pretomanid Tablets Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Pretomanid Tablets Market Size by Country
    • 11.3.1 Middle East & Africa Pretomanid Tablets Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Pretomanid Tablets Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Pretomanid Tablets Market Drivers
  • 12.2 Pretomanid Tablets Market Restraints
  • 12.3 Pretomanid Tablets Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Pretomanid Tablets and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Pretomanid Tablets
  • 13.3 Pretomanid Tablets Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Pretomanid Tablets Typical Distributors
  • 14.3 Pretomanid Tablets Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Pretomanid Tablets market size was valued at US$ 185 million in 2025 and is forecast to a readjusted size of US$ 400 million by 2032 with a CAGR of 10.0% during review period.
    Pretomanid tablets are a novel nitroimidazopyran anti-tuberculosis drug with potent bactericidal activity against multidrug-resistant tuberculosis. It exerts a bactericidal effect by inhibiting the synthesis of proteins and cell walls of Mycobacterium tuberculosis. As a core drug in the fully oral, long-course anti-tuberculosis regimen, it is often combined with bedaquiline and linezolid to form the BPaL regimen, for the treatment of extensively drug-resistant pulmonary tuberculosis or multidrug-resistant pulmonary tuberculosis with intolerance or ineffective conventional treatment. Featuring favorable oral absorption, strong tissue penetration and controllable safety, it is a core therapeutic drug for drug-resistant tuberculosis recommended by WHO, which significantly improves the cure rate of refractory tuberculosis.In 2025, global Pretomanid tablets production reached approximately 1,200,000 bottles
    As an innovative drug in the global anti-tuberculosis field, Pretomanid tablets are strategically positioned and developed based on the clinical demand for drug-resistant tuberculosis and the construction of public health systems. As a core component of the fully oral, short-course BPaL (or BPaLM) combination regimen, Pretomanid is mainly indicated for multidrug-resistant and extensively drug-resistant tuberculosis. With superior efficacy and safety compared with traditional regimens, it has become a core drug recommended by the World Health Organization for drug-resistant tuberculosis, driving the global shift from long-course, high-adverse-effect tuberculosis treatments to short-course, high-compliance regimens.
    In terms of market structure, the global market features a diversified supply pattern of innovator and generic drugs. The originator product developed by TB Alliance expands coverage in high-burden countries and low- and middle-income markets through multi-manufacturer authorization. Meanwhile, generic drugs qualified by WHO prequalification significantly improve drug accessibility via international public health procurement and regional supply chains, forming a supply system dominated by public health programs. In China, the approval and inclusion of Pretomanid in the medical insurance catalogue have substantially improved diagnosis and treatment accessibility and reduced patient burden, advancing domestic drug-resistant tuberculosis prevention and control into a new stage of highly effective and inclusive treatment.
    The core drivers of market growth lie in three aspects: first, the persistent global incidence of drug-resistant tuberculosis sustains strong demand for new and effective treatment regimens; second, countries gradually incorporate BPaL-based short-course regimens into national tuberculosis programs, accelerating clinical adoption and policy implementation; third, price optimization and multi-manufacturer deployment balance drug value and healthcare system costs, expanding accessibility. Meanwhile, market development faces challenges such as regional disparities in medical resources, standardized management of treatment regimens, and improvement of drug resistance monitoring systems. Further consolidation of its core position in drug-resistant tuberculosis therapy relies on public health cooperation, improved cross-regional supply chains, and continuous accumulation of real-world data.
    This report is a detailed and comprehensive analysis for global Pretomanid Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Pretomanid Tablets market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Pretomanid Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Pretomanid Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Pretomanid Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Pretomanid Tablets
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Pretomanid Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include TB Alliance, Macleods Pharmaceuticals, Lupin Limited, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Pretomanid Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    26 tablets/box
    182 tablets/bottle
    Market segment by Packaging
    Bottle
    Box
    Market segment by Storage
    Protect From Light
    Protect From Moisture
    Market segment by Production Technology
    Innovator
    Generic
    Market segment by Application
    Multidrug-Resistant Pulmonary Tuberculosis (MDR-TB)
    Extensively Drug-Resistant Pulmonary Tuberculosis (XDR-TB)
    Others
    Major players covered
    TB Alliance
    Macleods Pharmaceuticals
    Lupin Limited
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Pretomanid Tablets product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Pretomanid Tablets, with price, sales quantity, revenue, and global market share of Pretomanid Tablets from 2021 to 2026.
    Chapter 3, the Pretomanid Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Pretomanid Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Pretomanid Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Pretomanid Tablets.
    Chapter 14 and 15, to describe Pretomanid Tablets sales channel, distributors, customers, research findings and conclusion.

    Buy now